Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | FPR3 | P25089 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | POLR1A | O95602 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6395379 | 0.86 | ACKR3 (0.51) | ACKR3ALDH1A1FPR3FPR2CHRM4 | |
| SCHEMBL7963540 | 0.85 | ALDH1A1 (0.48) | ACKR3ALDH1A1FPR3FPR2CHRM4 | |
| SCHEMBL9887516 | 0.85 | ACKR3 (0.50) | ACKR3ALDH1A1FPR3FPR2CHRM4 | |
| SCHEMBL424247 | 0.85 | ALDH1A1 (0.48) | ACKR3ALDH1A1FPR3FPR2CHRM4 | |
| SCHEMBL12156865 | 0.83 | ACKR3 (0.52) | ACKR3ALDH1A1FPR3FPR2CHRM4 | |
| SCHEMBL12506716 | 0.82 | FAP (0.44) | ALDH1A1CHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL8320704 | 0.82 | FAP (0.44) | ALDH1A1CHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL12155765 | 0.82 | DPP4 (0.46) | ACKR3ALDH1A1FPR3FPR2CHRM4 | |
| SCHEMBL12788561 | 0.82 | ACKR3 (0.46) | ACKR3ALDH1A1FPR3FPR2CHRM4 | |
| SCHEMBL13817510 | 0.82 | FPR3 (0.47) | ACKR3ALDH1A1FPR3FPR2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020198583-A1 | BICYCLIC JAK INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2020-10-01 | — | — | WO | disclosed |
| US-10259796-B2 | Oxaspiro[2.5]octane derivatives and analogs | ZAFGEN, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-9920010-B2 | CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-03-20 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170044122-A1 | Oxaspiro[2.5]Octane Derivatives and Analogs | ZAFGEN, INC. (US) | 2017-02-16 | — | — | US | disclosed |
| US-20160107997-A1 | CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-04-21 | — | — | US | disclosed |
| US-20150352108-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON | ALZHEIMER'S INSTITUTE OF AMERICA (US) | 2015-12-10 | — | — | US | disclosed |
| US-8912185-B2 | Use of glutaric acid derivatives or the pharmaceutically acceptable salts thereof as anti-arrhythmic agents | Obschestvo S Ogranichennoi Otvetstvennostyu “Pharmenterprises” (RU) | 2014-12-16 | — | — | US | disclosed |
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070032487-A1 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2007-02-08 | — | — | US | disclosed |
| US-20070032487-A1 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2007-02-08 | — | — | US | disclosed |
| US-20070032490-A1 | N-Phenyl-'(4-pyridyl)-azinyl!amine derivatives as plant protection agents | SYNGENTA CROP PROTECTION, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032490-A1 | N-Phenyl-'(4-pyridyl)-azinyl!amine derivatives as plant protection agents | SYNGENTA CROP PROTECTION, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1688420-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2006-08-09 | — | — | EP | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160107997-A1 | CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, CXCR2 | ACKR3 7/4885ALDH1A1 997/4885FPR3 236/4885 |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | ACKR3 2614/4885ALDH1A1 750/4885FPR3 4330/4885 |
| US-20070032487-A1 | Inhibitors of phosphatidylinositol 3-kinase | PIK3CA, PIP4K2C, PIP4K2B | ACKR3 3292/4885ALDH1A1 4104/4885FPR3 3878/4885 |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | ACKR3 14/4885ALDH1A1 451/4885FPR3 26/4885 |
| US-10259796-B2 | Oxaspiro[2.5]octane derivatives and analogs | OXER1, ACOX3, OXGR1 | ACKR3 1071/4885ALDH1A1 411/4885FPR3 523/4885 |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | ACKR3 3386/4885ALDH1A1 351/4885FPR3 4156/4885 |
| US-20170044122-A1 | Oxaspiro[2.5]Octane Derivatives and Analogs | OXER1, ACOX3, OXGR1 | ACKR3 1071/4885ALDH1A1 411/4885FPR3 523/4885 |
| US-20070032490-A1 | N-Phenyl-'(4-pyridyl)-azinyl!amine derivatives as plant protection agents | CYP1A1, NAT1, AKR7A2 | ACKR3 4865/4885ALDH1A1 422/4885FPR3 2737/4885 |
| US-20150352108-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON | TBK1, NFKBIA, CHUK | ACKR3 1598/4885ALDH1A1 4754/4885FPR3 2126/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | ACKR3 1214/4885ALDH1A1 1079/4885FPR3 957/4885 |
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIP4K2C | ACKR3 3276/4885ALDH1A1 4151/4885FPR3 3897/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | ACKR3 1580/4885ALDH1A1 1563/4885FPR3 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.